Exploring the Future of Mental Health

New data shows cannabis dominates teens’ substance-related ER visits, often with alcohol or stimulants, urging better screening and intervention for psychosis, vomiting.

Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

The American Society of Addiction Medicine has released the first clinical guide and national resource for managing the intoxication and withdrawal of medetomidine.

In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.

Reach Out and Read serves 4.8 million children, but 23% of parents at 3 centers reported clinician modeling, tied to the greatest home literacy gains.

Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.

Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.